ClinicalTrials.gg
CompletedNCT02913261REACH2Updated Feb 8, 2023Results posted

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

A Phase 3 interventional study of Ruxolitinib (RUX) and Best Available Therapy (BAT) in Corticosteroid Refractory Acute Graft vs Host Disease, sponsored by Novartis Pharmaceuticals. Completed at 103 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.

Enrollment
4th of 27
310 · median 54
Started
2017
with 1 other
Phase 3
3 of 27
1 open now
Registered
2nd of 27
by date
Lead sponsor
6 of 27
Novartis Pharmaceuticals

Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 3, and was the 2nd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ruxolitinib in Graft vs Host Disease, or all of them as a file.
02

Study summary

Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.

Read the detailed description

This randomized, phase III, open-label study investigated the efficacy and safety of ruxolitinib vs. BAT added to the patient's immunosuppressive regimen in adults and adolescents (≥ 12 years old) with grade II-IV Steroid-refractory Acute Graft vs. Host Disease (SR-aGvHD). During the screening period, patients were monitored for a diagnosis of SR-aGvHD, which was defined as patients who had high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with CNI, who either:

  1. Progressed based on organ assessment after at least 3 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD, OR
  2. Failed to achieve at a minimum a partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD, OR
  3. Failed corticosteroid taper defined as fulfilling either one of the following criteria:

    • Requirement for an increase in the corticosteroid dose to methylprednisolone ≥ 2 mg/kg/day (or equivalent prednisone dose ≥ 2.5 mg/kg/day) OR
    • Failure to taper the methylprednisolone dose to \<0.5 mg/kg/day (or equivalent prednisone dose \<0.6 mg/kg/day) for a minimum 7 days.

Patients meeting eligibility criteria were randomized 1:1 to receive either ruxolitinib or BAT stratifying on aGvHD grade at the time of randomization (Grade II vs III vs IV).

Study treatment began on Day 1 (no later than 72 hours after randomization) followed by regular visits for assessments of efficacy and safety. Study treatment was administered until the patient met any of the criteria for discontinuation of study treatment or, in responders (i.e. patients achieving PR or CR) until the dosing schedule for ruxolitinib or BAT was completed.

All responders were to be tapered off during the treatment period by, first tapering from corticosteroids, followed by CNI and ruxolitinib. A slow tapering extending beyond 24 weeks was permitted for ruxolitinib at Investigator's discretion rather than an abrupt cessation, as the latter could result in an aGvHD flare.

During the Treatment Period, patients randomized to BAT could have crossed over to ruxolitinib between Day 28 and Week 24 if they:

  • Failed to meet the primary endpoint response definition (CR or PR) at Day 28 OR
  • Lost the response thereafter and met criteria for progression, mixed response, or no response, necessitating new additional systemic immunosuppressive treatment for aGvHD.

AND

  • Did not have signs/symptoms of chronic Graft vs. Host Disease (cGvHD) (overlap syndrome, progressive, or de novo cGvHD)

Patients who crossed over to ruxolitinib were followed until completion of treatment with ruxolitinib and received the same treatment and tapering schedule as patients randomized to ruxolitinib treatment.

The End of Treatment (EOT) visit occurred when the patient completed the study treatment period or earlier if the patient met any of the criteria for discontinuation of study treatment.

Patient's treatment period was up to 6 months (Week 24). However, ruxolitinib taper could be delayed up to 2 years from randomization due to an aGvHD flare or other safety concerns.

03

Conditions studied

  • Corticosteroid Refractory Acute Graft vs Host Disease

Browse trials for

Keywords

  • GvHD (Graft versus Host Disease)
  • INC424
  • ruxolitinib
  • best available therapy (BAT)
  • corticosteroid-refractory acute graft vs. host disease
  • allogeneic stem cell transplantation
  • steroid refractory acute graft vs. host disease
  • Janus Kinase (JAK) inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have undergone Stem Cell Transplanttaion (alloSCT) from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non- myeloablative, myeloablative, and reduced intensity conditioning are eligible
  • Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring after alloSCT requiring systemic immune suppressive therapy. of involved organs with aGvHD is encouraged but not required for study screening.
  • Confirmed diagnosis of aGvHD defined as patients administered high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:

    • Progressing based on organ assessment after at least 3 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD, OR
    • Failure to achieve at a minimum partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD,OR
    • Patients who fail corticosteroid taper defined as fulfilling either one of the following criteria:
  • Requirement for an increase in the corticosteroid dose to methylprednisolone ≥2 mg/kg/day (or equivalent prednisone dose ≥2.5 mg/kg/day) , OR
  • Failure to taper the methylprednisolone dose to \<0.5 mg/kg/day (or equivalent prednisone dose \<0.6 mg/kg/day) for a minimum 7 days.

Exclusion criteria

Exclusion Criteria:

  • Has received more than one systemic treatment for aGvHD.
  • Presence of an active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  • Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (), or Virus (HCV) based on assessment by the treating physician.
  • Presence of relapsed primary , or who have been treated for relapse after the was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    These patients were administered Ruxolitinib orally twice per day (b.i.d) at a dose of 10 mg bid, as two 5-mg tablets. Ruxolitinib was taken without regards to food.

    Drug: Ruxolitinib (RUX)

  • Active comparator
    Best Available Therapy (BAT)

    These patients were administered BAT per the Investigator's best judgement based on a specific list of BAT.

    Drug: Best Available Therapy (BAT)

Interventions

  • Ruxolitinib was provided as 5 mg tablets for oral use.

    Also known as: INC424

  • DrugBest Available Therapy (BAT)

    BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Day 28

    Overall response rate at Day 28 after randomization was defined as the percentage participants in each arm demonstrating a complete response (CR) or partial response (PR), based on investigator assessment \& according to standard criteria, without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response was relative to the organ stage at the time of randomization. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs \& symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: Day 28

Secondary outcomes

  1. Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56

    Percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: Day 56

  2. Overall Response Rate (ORR) at Day 14

    ORR at Da4 14 is the percentage of participants who achieved overall response (CR+PR) at Day 14 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: Day 14

  3. Duration of Response (DOR)

    Duration of response was defined for patients who had a CR or PR at Day 28. This was the interval between the date of first documented response of CR or PR (i.e., the start date of response), till the date of progression or addition of systemic therapies for aGvHD on or after Day 28. Death without prior observation of aGvHD progression and onset of chronic GvHD were considered. Duration of response was censored at the last response assessment prior to or at the analysis cut-off date, if no events/competing risk occurred before or at the cut-off date.

    Time frame: Up to 24 months

  4. Cumulative Steroid Dosing Until Day 56

    Weekly cumulative steroid dose for each participant up to Day 56 or discontinuation of randomized treatment. Participants should have undergone tapering of steroids if it had been required. Tapering the immunosuppression therapy was performed in 2 steps: Taper of corticosteroids: initiated not earlier than Day 7, and performed as per institutional guidelines. Only patients with assessments done at each time point are reported. This is the reason that the overall number per treatment is higher and the number of participants with responses vary over time.

    Time frame: up to Day 56

  5. Kaplan Meier Estimates of Probability of Overall Survival (OS) by Time Interval

    OS was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.

    Time frame: 1, 2, 6, 12, 18 & 24 months

  6. Kaplan Meier Estimates of Probability of Event-free Survival (EFS) by Time Interval

    Event-free survival was defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. If a patient was not known to have any event, then EFS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.

    Time frame: 1, 2, 6, 12, 18 & 24 months

  7. Cumulative Incidence Rate of Failure-Free Survival (FFS)

    FFS was defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. Probability of FFS with 95% CIs are presented for each treatment group, accounting for onset of chronic GvHD as the competing risk.

    Time frame: 1, 2, 6, 12, 18, & 24 Months

  8. Cumulative Probability of Non Relapse Mortality (NRM)

    NRM was defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression. Hematologic disease relapse/progression was considered a competing risk for NRM with the date of hematologic disease relapse/progression being the earlier of documented hematologic disease relapse/progression or institution of therapy to treat potential hematologic disease relapse/progression. If a patient was not known to have died or to have relapsed/progressed, then NRM was censored at the latest date the patient was known to be alive (on or before the cut-off date). Data is provided based on cumulative probability of hematologic disease relapse/progression.

    Time frame: 1, 2, 6, 12, 18 & 24 months

  9. Cumulative Probability of Malignancy Relapse/Progression (MR)

    MR was defined as the time from date of randomization to hematologic malignancy relapse/progression. Deaths not preceded by hematologic malignancy relapse/progression were considered competing risks. If a patient was not known to have event or competing risks, then MR was censored at the latest date the patient was known to be alive (on or before the cut-off date). Calculated for patients with underlying hematologic malignant disease.

    Time frame: 1, 2, 6, 12 , 18 & 24 months

  10. Cumulative Probability of Chronic Graft Versus Host Disease (cGvHD)

    Incidence of cGvHD was the time from date of randomization to onset of cGvHD is the diagnosis of any cGvHD including mild, moderate, severe. Deaths without prior onset of cGvHD and hematologic disease relapse/progression were competing risks. If a patient was not known to have event or competing risks, then the incidence of cGvHD was censored at the latest date the patient was known to be alive (on or before the cut-off date).

    Time frame: 1, 2, 6, 12, 18 & 24 months

  11. Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate

    Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. ORR was defined as the percentage of participants with a best overall response defined as complete response (CR) or partial response (PR) as assessed by local investigators. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: Day 28

  12. Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)

    Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. DORR is the percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: Day 56

  13. Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival

    Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. This represents the percentage of Ruxolitinib-exposed participants dead at 24 months. Overall survival (OS) was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date).the date of death due to any cause.

    Time frame: up to 24 months

  14. Best Overall Response Rate (BOR)

    Percentage of participants who achieved overall response (OR) (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

    Time frame: up to Day 28

  15. Patient Reported Outcomes (PROs): Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Total Score

    The Functional assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family and emotional well-being, together with additional concerns relevant for bone marrow transplantation patients. Patients indicated their response on a scale of 0 to 4 on each statement, with 0 indicating worst score and 4 the best score. All individual scores were combined to calculate the total score. Total score was reported with score range: 0-148 which was calculated as the sum of all unweighted subscale scores. The higher the total score the better the result. Descriptive statistics and change from baseline were calculated in total score at each scheduled assessment time point.

    Time frame: Baseline, Week 24

  16. Patient Reported Outcomes (PROs): Change From Baseline in EuroQol-5D-5L UK Score

    The EQ-5D descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression and pain/discomfort. Patients are requested to select the statement which best describes their condition on that day for each dimension. For overall health that day, the EuroQoL-5D-5L scale is numbered from 0 to 100, with 100 being the best health you can imagine and 0 being the worst health you can imagine. Descriptive statistics (mean, standard deviation, median, Q1, Q3, minimum, and maximum) were calculated based on the scored scales at each scheduled assessment time point. In order to measure Quality-of-Life (QoL) among aGvHD patients, and potential changes over time, change from baseline in EuroQol-5D-5L scores at the time of each assessment were also calculated. Missing items data in a scale will be handled based on each instrument manual. No imputation will be applied if the total or subscale scores are missing at a visit.

    Time frame: Baseline, Week 24

  17. Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC) (AUCinf, AUClast, AUCtau) of Ruxolitinib

    AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) AUCinf: The AUC from time zero to infinity (mass x time x volume-1) AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  18. Pharmacokinetic (PK) Parameter: Plasma Concentration at Peak (Cmax) of Ruxolitinib

    Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass X volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  19. Pharmacokinetic (PK) Parameter: CL/F of Ruxolitinib

    CL/F is the total body clearance of ruxolitinib from the plasma after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for Ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  20. Pharmacokinetic (PK) Parameter: VzF of Ruxolitinib

    VzF is the apparent volume of distribution during terminal phase after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  21. Pharmacokinetic (PK) Parameter: Lambda_z of Ruxolitinib

    Lambda_z is the smallest (slowest) disposition (hybrid) rate constant (hr-1) may also be used for terminal elimination rate constant (hr-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  22. Pharmacokinetic (PK) Parameter: T1/2 of Ruxolitinib

    T1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  23. Pharmacokinetic (PK) Parameter: Tmax of Ruxolitinib

    Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose and repeated dose administration (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  24. Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib

    Racc is the accumulation ratio (AUC at steady state/AUC Day 1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

    Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose

  25. Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib

    Minimum concentration (Ctrough) of ruxolitinib and at steady state in corticosteroid refractory acute GVHD patients. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS)

    Time frame: pre-dose

07

Results

Posted Feb 8, 2023

Participant flow

A total of 310 patients with SR-aGvHD were enrolled, out of which 309 patients were included in the analysis (as one patient did not sign the study informed consent prior to receiving BAT (protocol deviation) and was excluded from all analyses). Completed = Completed the treatment period Not completed = Discontinued from treatment period

Participant flow — Overall Study
MilestoneRuxolitinib (RUX)Best Available Therapy (BAT)
Started154155
Not treated25
Crossover treatment at end of randomized treatment049
Entered long-term follow-up10251
Completed screening & randomized154155
Completed screening & not randomized01
Completed3520
Not completed119135
Withdrew: Technical problems01
Withdrew: Lack of efficacy3269
Withdrew: Adverse event275
Withdrew: Death2522
Withdrew: Failure to meet protocol continuation criteria1310
Withdrew: Disease relapse813
Withdrew: Physician decision89
Withdrew: Subject/guardian decision46
Withdrew: Graft loss20

Outcome measures

PrimaryOverall Response Rate (ORR) at Day 28

Overall response rate at Day 28 after randomization was defined as the percentage participants in each arm demonstrating a complete response (CR) or partial response (PR), based on investigator assessment \& according to standard criteria, without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response was relative to the organ stage at the time of randomization. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs \& symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at Day 28
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
Overall Response Rate (ORR) at Day 2862.3 (54.2 to 70.0)39.4 (31.6 to 47.5)
Statistical analysis
  • Ruxolitinib (RUX) vs Best Available Therapy (BAT) · Stratified Cochran-Mantel-Haenszel · p = <.0001 · Odds ratio (or): 2.64 · 95% CI 1.65 to 4.22
SecondaryDurable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56

Percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
Day 56
Reported as:
Number · Percentage of participants
Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 5639.6 (31.8 to 47.8)21.9 (15.7 to 29.3)
Statistical analysis
  • Ruxolitinib (RUX) vs Best Available Therapy (BAT) · Stratified Cochran-Mantel-Haenszel · p = 0.0005 · Odds ratio (or): 2.38 · 95% CI 1.43 to 3.94
SecondaryOverall Response Rate (ORR) at Day 14

ORR at Da4 14 is the percentage of participants who achieved overall response (CR+PR) at Day 14 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
Day 14
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at Day 14
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
Overall Response Rate (ORR) at Day 1463.0 (54.8 to 70.6)47.1 (39.0 to 55.3)
Statistical analysis
  • Ruxolitinib (RUX) vs Best Available Therapy (BAT) · Stratified Cochran-Mantel-Haenszel · p = 0.0029 · Odds ratio (or): 1.98 · 95% CI 1.24 to 3.17
SecondaryDuration of Response (DOR)

Duration of response was defined for patients who had a CR or PR at Day 28. This was the interval between the date of first documented response of CR or PR (i.e., the start date of response), till the date of progression or addition of systemic therapies for aGvHD on or after Day 28. Death without prior observation of aGvHD progression and onset of chronic GvHD were considered. Duration of response was censored at the last response assessment prior to or at the analysis cut-off date, if no events/competing risk occurred before or at the cut-off date.

Time frame:
Up to 24 months
Reported as:
Median · Days
Duration of Response (DOR)
DaysRuxolitinib (RUX)Best Available Therapy (BAT)
Duration of Response (DOR)167.0 (22.0 to 677.0)106.0 (10.0 to 526.0)
SecondaryCumulative Steroid Dosing Until Day 56

Weekly cumulative steroid dose for each participant up to Day 56 or discontinuation of randomized treatment. Participants should have undergone tapering of steroids if it had been required. Tapering the immunosuppression therapy was performed in 2 steps: Taper of corticosteroids: initiated not earlier than Day 7, and performed as per institutional guidelines. Only patients with assessments done at each time point are reported. This is the reason that the overall number per treatment is higher and the number of participants with responses vary over time.

Time frame:
up to Day 56
Reported as:
Median · mg
Cumulative Steroid Dosing Until Day 56
mgRuxolitinib (RUX)Best Available Therapy (BAT)
By Week 1962.5 (140.0 to 2337.5)923.6 (140.0 to 6093.8)
By Week 21740.0 (280.0 to 3500.0)1725.0 (280.0 to 7173.3)
By Week 32375.0 (350.0 to 5250.0)2340.0 (370.0 to 8000.0)
By Week 42866.9 (420.0 to 7000.0)2816.3 (420.0 to 9050.0)
By Week 53268.1 (455.0 to 8750.0)3290.6 (420.0 to 9825.0)
By Week 63606.3 (490.0 to 10500.0)3543.8 (420.0 to 10435.0)
By Week 73850.0 (495.0 to 11250.0)3706.3 (420.0 to 10955.0)
By Week 84000.0 (857.5 to 9475.0)4006.3 (420.0 to 11875.0)
SecondaryKaplan Meier Estimates of Probability of Overall Survival (OS) by Time Interval

OS was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.

Time frame:
1, 2, 6, 12, 18 & 24 months
Reported as:
Number · Percentage of participants
Kaplan Meier Estimates of Probability of Overall Survival (OS) by Time Interval
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month90.04 (84.02 to 93.87)85.48 (78.79 to 90.19)
2 Months77.95 (70.42 to 83.79)75.69 (67.92 to 81.83)
6 Months58.38 (50.03 to 65.82)49.42 (40.89 to 57.37)
12 Months49.27 (40.96 to 57.05)42.71 (34.39 to 50.75)
18 Months42.94 (34.82 to 50.79)37.97 (29.86 to 46.03)
24 Months38.65 (30.50 to 46.72)35.55 (27.57 to 43.59)
SecondaryKaplan Meier Estimates of Probability of Event-free Survival (EFS) by Time Interval

Event-free survival was defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. If a patient was not known to have any event, then EFS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.

Time frame:
1, 2, 6, 12, 18 & 24 months
Reported as:
Number · Percentage of participants
Kaplan Meier Estimates of Probability of Event-free Survival (EFS) by Time Interval
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month89.38 (83.24 to 93.35)82.83 (75.81 to 87.97)
2 Months74.60 (66.82 to 80.82)71.72 (63.71 to 78.26)
6 Months53.68 (45.34 to 61.30)44.14 (35.82 to 52.13)
12 Months44.53 (36.36 to 52.36)39.98 (30.90 to 46.96)
18 Months40.29 (32.30 to 48.12)35.09 (27.23 to 43.04)
24 Months34.98 (27.01 to 43.04)32.38 (24.61 to 40.37)
SecondaryCumulative Incidence Rate of Failure-Free Survival (FFS)

FFS was defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. Probability of FFS with 95% CIs are presented for each treatment group, accounting for onset of chronic GvHD as the competing risk.

Time frame:
1, 2, 6, 12, 18, & 24 Months
Reported as:
Number · Cumulative probability of FFS
Cumulative Incidence Rate of Failure-Free Survival (FFS)
Cumulative probability of FFSRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month17.92 (12.26 to 24.46)49.13 (40.94 to 56.80)
2 Months35.39 (27.79 to 43.07)61.32 (53.00 to 68.61)
6 Months53.67 (45.28 to 61.34)80.17 (72.52 to 85.89)
12 Months58.64 (50.18 to 66.16)80.91 (73.32 to 86.54)
18 Months59.35 (50.88 to 66.84)80.91 (73.32 to 86.54)
24 Months61.48 (53.01 to 68.88)81.66 (74.12 to 87.19)
SecondaryCumulative Probability of Non Relapse Mortality (NRM)

NRM was defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression. Hematologic disease relapse/progression was considered a competing risk for NRM with the date of hematologic disease relapse/progression being the earlier of documented hematologic disease relapse/progression or institution of therapy to treat potential hematologic disease relapse/progression. If a patient was not known to have died or to have relapsed/progressed, then NRM was censored at the latest date the patient was known to be alive (on or before the cut-off date). Data is provided based on cumulative probability of hematologic disease relapse/progression.

Time frame:
1, 2, 6, 12, 18 & 24 months
Reported as:
Number · Cumulative probability of NRM
Cumulative Probability of Non Relapse Mortality (NRM)
Cumulative probability of NRMRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month9.96 (5.83 to 15.39)14.52 (9.45 to 20.64)
2 Months20.71 (14.61 to 27.54)23.54 (17.04 to 30.65)
6 Months37.59 (29.81 to 45.33)42.42 (34.18 to 50.41)
12 Months43.91 (35.75 to 51.77)46.11 (37.68 to 54.12)
18 Months46.03 (37.77 to 53.89)49.21 (40.63 to 57.22)
24 Months49.53 (40.91 to 57.55)49.99 (41.38 to 57.99)
SecondaryCumulative Probability of Malignancy Relapse/Progression (MR)

MR was defined as the time from date of randomization to hematologic malignancy relapse/progression. Deaths not preceded by hematologic malignancy relapse/progression were considered competing risks. If a patient was not known to have event or competing risks, then MR was censored at the latest date the patient was known to be alive (on or before the cut-off date). Calculated for patients with underlying hematologic malignant disease.

Time frame:
1, 2, 6, 12 , 18 & 24 months
Reported as:
Number · Cumulative probability of MR
Cumulative Probability of Malignancy Relapse/Progression (MR)
Cumulative probability of MRRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month0.69 (0.06 to 3.51)2.80 (0.92 to 6.54)
2 Months4.21 (1.73 to 8.46)4.29 (1.75 to 8.60)
6 Months8.46 (4.60 to 13.79)13.49 (8.32 to 19.91)
12 Months10.68 (6.24 to 16.47)15.06 (9.56 to 21.71)
18 Months12.91 (7.96 to 19.09)16.72 (10.89 to 23.64)
24 Months14.75 (9.32 to 21.37)18.81 (12.46 to 26.17)
SecondaryCumulative Probability of Chronic Graft Versus Host Disease (cGvHD)

Incidence of cGvHD was the time from date of randomization to onset of cGvHD is the diagnosis of any cGvHD including mild, moderate, severe. Deaths without prior onset of cGvHD and hematologic disease relapse/progression were competing risks. If a patient was not known to have event or competing risks, then the incidence of cGvHD was censored at the latest date the patient was known to be alive (on or before the cut-off date).

Time frame:
1, 2, 6, 12, 18 & 24 months
Reported as:
Number · Cumulative probability of cGvHD
Cumulative Probability of Chronic Graft Versus Host Disease (cGvHD)
Cumulative probability of cGvHDRuxolitinib (RUX)Best Available Therapy (BAT)
1 Month0 (NA to NA)1.33 (0.26 to 4.34)
2 Months1.34 (0.26 to 4.39)2.03 (0.55 to 5.41)
6 Months15.60 (10.26 to 21.96)12.19 (7.40 to 18.25)
12 Months29.66 (22.41 to 37.25)20.24 (13.98 to 27.34)
18 Months32.48 (24.96 to 40.20)23.36 (16.62 to 30.76)
24 Months36.00 (28.20 to 43.84)24.95 (18.00 to 32.50)
SecondaryExposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate

Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. ORR was defined as the percentage of participants with a best overall response defined as complete response (CR) or partial response (PR) as assessed by local investigators. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate
Percentage of participantsRuxolitinib (RUX)
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate82.2
SecondaryExposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)

Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. DORR is the percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
Day 56
Reported as:
Number · Percentage of participants
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)
Percentage of participantsRuxolitinib (RUX)
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)91.0
SecondaryExposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival

Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. This represents the percentage of Ruxolitinib-exposed participants dead at 24 months. Overall survival (OS) was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date).the date of death due to any cause.

Time frame:
up to 24 months
Reported as:
Number · Percentage of participants
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival
Percentage of participantsRuxolitinib (RUX)
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival53.3
SecondaryBest Overall Response Rate (BOR)

Percentage of participants who achieved overall response (OR) (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Time frame:
up to Day 28
Reported as:
Number · Percentage of participants
Best Overall Response Rate (BOR)
Percentage of participantsRuxolitinib (RUX)Best Available Therapy (BAT)
Best Overall Response Rate (BOR)81.8 (74.8 to 87.6)60.6 (52.5 to 68.4)
Statistical analysis
  • Ruxolitinib (RUX) vs Best Available Therapy (BAT) · Stratified Cochran-Mantel-Haenszel · p = <.0001 · Odds ratio (or): 3.07 · 95% CI 1.80 to 5.25
SecondaryPatient Reported Outcomes (PROs): Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Total Score

The Functional assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family and emotional well-being, together with additional concerns relevant for bone marrow transplantation patients. Patients indicated their response on a scale of 0 to 4 on each statement, with 0 indicating worst score and 4 the best score. All individual scores were combined to calculate the total score. Total score was reported with score range: 0-148 which was calculated as the sum of all unweighted subscale scores. The higher the total score the better the result. Descriptive statistics and change from baseline were calculated in total score at each scheduled assessment time point.

Time frame:
Baseline, Week 24
Reported as:
Median · scores on a scale
Patient Reported Outcomes (PROs): Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Total Score
scores on a scaleRuxolitinib (RUX)Best Available Therapy (BAT)
Baseline89.00 (41.0 to 138.0)81.00 (29.0 to 129.0)
Week (W) 24108.50 (67.0 to 139.0)86.00 (21.0 to 124.0)
Change from Baseline to W249.00 (-40.0 to 44.0)4.50 (-29.0 to 41.0)
SecondaryPatient Reported Outcomes (PROs): Change From Baseline in EuroQol-5D-5L UK Score

The EQ-5D descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression and pain/discomfort. Patients are requested to select the statement which best describes their condition on that day for each dimension. For overall health that day, the EuroQoL-5D-5L scale is numbered from 0 to 100, with 100 being the best health you can imagine and 0 being the worst health you can imagine. Descriptive statistics (mean, standard deviation, median, Q1, Q3, minimum, and maximum) were calculated based on the scored scales at each scheduled assessment time point. In order to measure Quality-of-Life (QoL) among aGvHD patients, and potential changes over time, change from baseline in EuroQol-5D-5L scores at the time of each assessment were also calculated. Missing items data in a scale will be handled based on each instrument manual. No imputation will be applied if the total or subscale scores are missing at a visit.

Time frame:
Baseline, Week 24
Reported as:
Median · scores on a scale
Patient Reported Outcomes (PROs): Change From Baseline in EuroQol-5D-5L UK Score
scores on a scaleRuxolitinib (RUX)Best Available Therapy (BAT)
Baseline0.60 (-0.6 to 1.0)0.54 (-0.6 to 1.0)
W240.78 (0.4 to 1.0)0.68 (-0.1 to 1.0)
Change from Baseline to W240.12 (-0.3 to 1.1)0.12 (-0.2 to 0.3)
SecondaryPharmacokinetic (PK) Parameter: Area Under the Curve (AUC) (AUCinf, AUClast, AUCtau) of Ruxolitinib

AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) AUCinf: The AUC from time zero to infinity (mass x time x volume-1) AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC) (AUCinf, AUClast, AUCtau) of Ruxolitinib
ng*hr/mLRuxolitinib (RUX)
Week 1 Day 1 AUCinf529.6 ± 55.2
Week 1 Day 1 AUClast522.9 ± 89.6
Week 1 Day 1 AUCtau578.9 ± 97.5
Week 1 Day 7 AUCinf440.9 ± 91.5
Week 1 Day 7 AUClast597.3 ± 73.2
Week 1 Day 7 AUCtau651.9 ± 86.4
SecondaryPharmacokinetic (PK) Parameter: Plasma Concentration at Peak (Cmax) of Ruxolitinib

Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass X volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetic (PK) Parameter: Plasma Concentration at Peak (Cmax) of Ruxolitinib
ng/mLRuxolitinib (RUX)
Week 1 Day 1118 ± 70.4
Week 1 Day 7129.3 ± 76.0
SecondaryPharmacokinetic (PK) Parameter: CL/F of Ruxolitinib

CL/F is the total body clearance of ruxolitinib from the plasma after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for Ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · L/hr
Pharmacokinetic (PK) Parameter: CL/F of Ruxolitinib
L/hrRuxolitinib (RUX)
Week 1 Day 1 CL/F18.88 ± 55.2
Week 1 Day 7 CL/F23.31 ± 89.4
SecondaryPharmacokinetic (PK) Parameter: VzF of Ruxolitinib

VzF is the apparent volume of distribution during terminal phase after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · Liters (L)
Pharmacokinetic (PK) Parameter: VzF of Ruxolitinib
Liters (L)Ruxolitinib (RUX)
Week 1 Day 152.57 ± 46.4
Week 1 Day 766.76 ± 71.6
SecondaryPharmacokinetic (PK) Parameter: Lambda_z of Ruxolitinib

Lambda_z is the smallest (slowest) disposition (hybrid) rate constant (hr-1) may also be used for terminal elimination rate constant (hr-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · 1/hr
Pharmacokinetic (PK) Parameter: Lambda_z of Ruxolitinib
1/hrRuxolitinib (RUX)
Week 1 Day 10.3592 ± 34.2
Week 1 Day 70.3492 ± 31.0
SecondaryPharmacokinetic (PK) Parameter: T1/2 of Ruxolitinib

T1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · hour (hr)
Pharmacokinetic (PK) Parameter: T1/2 of Ruxolitinib
hour (hr)Ruxolitinib (RUX)
Week 1 Day 11.93 ± 34.2
Week 1 Day 71.985 ± 31.0
SecondaryPharmacokinetic (PK) Parameter: Tmax of Ruxolitinib

Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose and repeated dose administration (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Median · hour (hr)
Pharmacokinetic (PK) Parameter: Tmax of Ruxolitinib
hour (hr)Ruxolitinib (RUX)
Week 1 Day 11.767 (0.5167 to 8.917)
Week 1 Day 71.542 (0.5 to 4.083)
SecondaryPharmacokinetic (PK) Parameter: Racc of Ruxolitinib

Racc is the accumulation ratio (AUC at steady state/AUC Day 1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).

Time frame:
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Reported as:
Geometric mean · ratio
Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib
ratioRuxolitinib (RUX)
Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib1.145 ± 27.2
SecondaryPharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib

Minimum concentration (Ctrough) of ruxolitinib and at steady state in corticosteroid refractory acute GVHD patients. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS)

Time frame:
pre-dose
Reported as:
Geometric mean · ng/ml
Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib
ng/mlRuxolitinib (RUX)
Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib17.22 ± 187.1
Post-hocAll Collected Deaths

On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 708 days (treatment duration ranged from 6.0 to 678.0) for the RUX arm and 218 days (treatment duration ranged from 1.0 to 188.0 days) for the BAT arm. Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 48 months. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.

Time frame:
approx. 708 days (AEs), up to approx. 48 months (deaths)
Reported as:
Number · Participants
All Collected Deaths
ParticipantsRuxolitinib (RUX)Best Available Therapy (BAT)Cross-Over
Total Deaths898929
Deaths on-treatment433619

Adverse events

Collected over On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 708 days (treatment duration ranged from 6.0 to 678.0) for the RUX arm and 218 days (treatment duration ranged from 1.0 to 188.0 days) for the BAT arm. Deaths occurred from Randomization till end of the study, up to approx. 48 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib (Rux)89/152 (58.6%)101/152 (66.4%)144/152 (94.7%)
Best Available Therapy (BAT)89/150 (59.3%)80/150 (53.3%)136/150 (90.7%)
Cross-Over29/49 (59.2%)38/49 (77.6%)43/49 (87.8%)
Most frequent serious events
Showing 10 of 218
Most frequent serious events
EventRuxolitinib (Rux)Best Available Therapy (BAT)Cross-Over
SepsisInfections and infestations12/15210/1507/49
Respiratory failureRespiratory, thoracic and mediastinal disorders6/1526/1506/49
PyrexiaGeneral disorders10/1526/1500/49
Septic shockInfections and infestations10/1528/1503/49
PneumoniaInfections and infestations7/1528/1502/49
DiarrhoeaGastrointestinal disorders8/1523/1500/49
ThrombocytopeniaBlood and lymphatic system disorders2/1520/1502/49
Gastrointestinal haemorrhageGastrointestinal disorders2/1521/1502/49
IleusGastrointestinal disorders1/1521/1502/49
Cytomegalovirus infection reactivationInfections and infestations3/1526/1502/49
Most frequent other events
Showing 10 of 64
Most frequent other events
EventRuxolitinib (Rux)Best Available Therapy (BAT)Cross-Over
AnaemiaBlood and lymphatic system disorders61/15247/15016/49
ThrombocytopeniaBlood and lymphatic system disorders56/15230/15014/49
Cytomegalovirus infection reactivationInfections and infestations38/15230/1508/49
Oedema peripheralGeneral disorders37/15232/1505/49
NeutropeniaBlood and lymphatic system disorders36/15219/15010/49
HypokalaemiaMetabolism and nutrition disorders34/15228/15010/49
Platelet count decreasedInvestigations31/15224/1506/49
NauseaGastrointestinal disorders30/15216/1503/49
PyrexiaGeneral disorders29/15221/1509/49
VomitingGastrointestinal disorders25/15216/1505/49

Baseline characteristics

Full Analysis Set (FAS): The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization.

Age, Continuous
Age, Continuous(years)Ruxolitinib (RUX)Best Available Therapy (BAT)Total
Mean48.1 ± 16.3050.9 ± 14.9749.5 ± 15.69
Age, Customized
Age, Customized(Participants)Ruxolitinib (RUX)Best Available Therapy (BAT)Total
Adolescents, 12 - <18 years549
18 - 65 years128126254
>65 years212546
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib (RUX)Best Available Therapy (BAT)Total
Female6264126
Male9291183
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib (RUX)Best Available Therapy (BAT)Total
White111102213
Black or African American011
Asian192948
Other8412
Unknown161935
Weight
Weight(kg)Ruxolitinib (RUX)Best Available Therapy (BAT)Total
Mean67.5 ± 14.0466.2 ± 14.7866.9 ± 14.41
08

Study locations

103 sites
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3002, Australia
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Linz, A-4010, Austria
  • Novartis Investigative Site
    Sofia, 1797, Bulgaria
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
  • Novartis Investigative Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Novartis Investigative Site
    Praha 2, Czech Republic 128 20, Czechia
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Saint Priest en Jarez, Loire 42270, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Besancon cedex, 25030, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Limoges cedex, 87042, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Paris Cedex 10, 75475, France
  • Novartis Investigative Site
    Paris Cedex, 75019, France
  • Novartis Investigative Site
    Paris, 75012, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy cedex, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Augsburg, 86179, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Thessaloniki, GR 570 10, Greece
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petach Tikva, 4941492, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    San Giovanni Rotondo, FG 71013, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 453-8511, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Sapporo city, Hokkaido 060 8648, Japan
  • Novartis Investigative Site
    Kobe-city, Hyogo 650-0047, Japan
  • Novartis Investigative Site
    Nishinomiya, Hyogo 663 8501, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 259-1193, Japan
  • Novartis Investigative Site
    Sendai city, Miyagi 980 8574, Japan
  • Novartis Investigative Site
    Okayama-city, Okayama 700-8558, Japan
  • Novartis Investigative Site
    Suita city, Osaka 565 0871, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8677, Japan
  • Novartis Investigative Site
    Chuo ku, Tokyo 104 0045, Japan
  • Novartis Investigative Site
    Minato ku, Tokyo 105-8470, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160 8582, Japan
  • Novartis Investigative Site
    Osaka, 545-8586, Japan
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Utrecht, The Netherlands 3508 GA, Netherlands
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Oviedo, Asturias 33006, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Vigo, Pontevedra 36212, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Malaga, 29009, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Istanbul, 41400, Turkey
  • Novartis Investigative Site
    Izmir, Turkey

Showing the first 100 of 103 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socie G; REACH2 Trial Group. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. PubMed 32320566 ↗
  • Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10. PubMed 29316837 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jun 2019, 27 months.

Results were first posted in Feb 2023, 3 years 7 months after primary completion.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2016
First posted
Sep 23, 2016
StartActual
Mar 10, 2017
Primary completionActual
Jun 24, 2019
CompletionActual
Apr 23, 2021
Results first posted
Feb 8, 2023
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02913261
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Mar 10, 2017
Primary completion
Jun 24, 2019
Completion
Apr 23, 2021
Results posted
Feb 8, 2023
Last update
Feb 8, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion